Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Labs Starts China Phase III Trial of Lead Drug in Ovarian Cancer

publication date: Sep 29, 2017

Shanghai's Zai Lab has dosed the first patient in a China Phase III trial of its lead drug, a PARP inhibitor. ZL-2306 (niraparib) will be tested as a second-line maintenance therapy in patients with platinum-responsive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer. Tesaro, from whom Zai in-licensed greater China rights to the drug in 2016, was approved to market niraparib in the US earlier this year for these indications. Last week, Zai staged a very successful US IPO, raising $172.5 million. More details....

Stock Symbols: (NSDQ: ZLAB) (NSDQ: TSRO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.